Cangrelor During Minimally Invasive Heart Bypass Surgery for Coronary Artery Disease
Checks if cangrelor drip is safe during minimally invasive bypass surgery in adults.
Plain-language title generated from the registry record
Registry title: Minimally Invasive Coronary Artery Bypass Supported by Cangrelor
Key facts
- Where
- Lugano, SwitzerlandSee the site
Where in Switzerland
- Istituto Cardiocentro TicinoLugano, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cardiocentro Ticino
- Trial code
- NCT07514962
- Record updated
- 14 April 2026
- Original description
The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip.Read full original descriptionShow less
Minimally Invasive Coronary Artery Bypass Supported by Cangrelor
The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip.
The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand.
Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications?
Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure.
This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.
Inclusion: Age ≥18 years old; CABG with IMA-LAD graft in MIDCAB technique; Age ≥18 years old; CABG with IMA-LAD graft in MIDCAB technique; Signed informed consent.
Exclusion: Administration of fibrinolytics or GP IIb/IIIa inhibitors; Previous intracranial hemorrhage; Patients undergoing concomitant PCI and MIDCAB; Recent administration of fibrinolytics or GP IIb/IIIa inhibitors; Previous intracranial hemorrhage; Patients undergoing concomitant PCI and MIDCAB; Known bleeding diathesis; Severe renal or liver disease; Known hypersensitivity to study drug (cangrelor); Known bleeding diathesis; Severe renal or liver disease; Pregnancy or breast feeding; Unconsciousness; Pregnancy or breast feeding.